December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

20.97 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 50
Open 20.97
Bid (Size) 20.86 (2)
Ask (Size) 21.73 (2)
Prev. Close 20.97
Today's Range 20.97 - 20.97
52wk Range 19.05 - 26.58
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Shows Strong Fundamentals and Technical Breakout Potential
Discover Catalyst Pharmaceuticals (CPRX), a biopharma stock with strong EPS growth, high profitability, and a bullish technical breakout pattern. 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Case for Affordable Growth
Discover Catalyst Pharmaceuticals (CPRX), a biopharma stock with strong growth, solid earnings, and an affordable valuation for investors seeking value. 
Via Chartmill

Performance

YTD
-2.6%
-2.6%
1 Month
+6.4%
+6.4%
3 Month
-1.7%
-1.7%
6 Month
-13.6%
-13.6%
1 Year
-2.7%
-2.7%

More News

Read More
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
What Does the Market Think About Catalyst Pharmaceuticals Inc?
Via Benzinga
Earnings Scheduled For August 6, 2025
Via Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investment with Strong Fundamentals
Via Chartmill
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Case for Affordable Growth
Via Chartmill
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investing Opportunity with Strong Fundamentals
Via Chartmill
How Is The Market Feeling About Catalyst Pharmaceuticals?
Via Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Investment with Strong Growth and Reasonable Valuation
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a High-Quality Caviar Cruise Candidate
Via Chartmill
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Value Investment in Biotech
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Top Affordable Growth Stock with Strong Fundamentals
Via Chartmill
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Fits Louis Navellier’s Growth Investing Strategy with Strong Earnings Momentum and Rising Sales
Via Chartmill
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with Breakout Potential
Via Chartmill
Is the Market Bullish or Bearish on Catalyst Pharmaceuticals?
Via Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – A Value Stock with Strong Fundamentals and Growth Potential
Via Chartmill

Frequently Asked Questions

Is Catalyst Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Catalyst Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Catalyst Pharmaceuticals, Inc. - Common Stock trade on?
Catalyst Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Catalyst Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Catalyst Pharmaceuticals, Inc. - Common Stock is CPRX on the Nasdaq Stock Market
What is the current price of Catalyst Pharmaceuticals, Inc. - Common Stock?
The current price of Catalyst Pharmaceuticals, Inc. - Common Stock is 20.97
When was Catalyst Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Catalyst Pharmaceuticals, Inc. - Common Stock was at 10/30/25 04:00 PM ET
What is the market capitalization of Catalyst Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Catalyst Pharmaceuticals, Inc. - Common Stock is 2.16B
How many shares of Catalyst Pharmaceuticals, Inc. - Common Stock are outstanding?
Catalyst Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.